Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
15
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go:
Expired
investment:
£543,670
YoungPlanet enables parents to put their children's unused things to use with new families and away from landfills for free via its app. The company cites PwC data estimating the UK’s sharing economy to be worth £9 billion by 2025. It aims to be a contender in this segment. The company argues further that 10-year-olds in the UK will own on average 238 toys at any one time and yet play with just 12. This leads to UK households wasting over 25 million tonnes a year, with one-fourth of this number ending up in landfills as per the Department for Environment, Food and Rural Affairs (DEFRA). YoungPlanet aims to change this. It has onboarded 36,000 users on its platform to date and featured in press publications such as BBC News, Vanessa Feltz, and LadBible. YoungPlanet will use the investment to scale nationally, begin generating first phase revenue via brand sponsorship of events, branded gamification, and Business-to-Business (B2B) subscriptions for semi-closed communities via its app.
days to go:
Expired
investment:
£547,103
Value Chain Lab streamlines supply chains by removing logistics waste.
http://www.valuechainlab.com/
days to go:
Expired
investment:
£330,874
Propio offers The Property ISA, a tax-efficient, simple and affordable way to invest in properties. The company aims to become the UK’s largest property-based ISA by making the experience of investing as straightforward as online shopping. Propio is powered by a team of property and finance heavyweights who hand-select all the investments, helping the customers reduce risks and earn stable, tax-free returns, irrespective of market fluctuation. The company’s client base comprises 1000+ customers who have invested over £7.5m in it. According to TrustPilot, Propio is among the top 10 investment companies in the UK, delivering average returns of 6.5% to investors, despite Brexit and stock market turmoil. Moreover, the company has partnered with two UK finance and property firms and expects an investment deal flow of up to £100m by 2021-22.
days to go:
Expired
investment:
£357,660
The first regulated crowdfunding business in the UK offering investment opportunities in environmental, ethical and social companies. Since 2011, Abundance has funded 34 investments totalling more than £75m, whilst delivering gross returns of 4-15% per year across renewable energy, social housing and sustainability projects. This equates to total interest returns of £12.1m. More than 5,250 investors on the platform have contributed funds almost 5 times on average over various campaigns.
Abundance also offers an IFISA product and as at April 2018, they have 8% of the IFISA market, which equates to over 2,900 ISA customers. The business’s investor's numbers have grown 52% since January 2017 and in the past year their customer portfolio has seen a 30% increase. In the last 3 years, marketing expenditure efficiency has also improved by 76%.
Abundance's services are free-to-use for investors. This means there are no fees for investing or withdrawing funds in opportunities or ISA products. Revenue is generated from borrowers who are seeking to raise finance for their projects. This is in the form of a set-up fee and a regular admin fee per year.
The business is crowdfunding to expand on the types of projects they currently offer, as a means to attract a wider range of investors. In addition, Abundance aims to market the campaigns on the platform through numerous channels and upgrade the technology they currently use to enhance the user experience.
days to go:
Expired
investment:
£1,621,138
